Navigation Links
Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
Date:5/12/2008

for our planned trials in a timely manner; our need for capital, which may not be available on a timely basis, or at all; risks associated with requirements for approvals by government agencies such as the FDA before products can be tested in clinical trials; the possibility that such government agency approvals will not be obtained in a timely manner or at all or will be conditioned in a manner that would impair our ability to advance development; risks associated with the requirement that a drug candidate be found safe and effective after extensive clinical trials; our dependence on suppliers, collaborative partners and other third parties and the prospects and timing for obtaining clinical supply materials; our ability to attract and retain key personnel; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at http://www.sedar.com.

Assumptions underlying our expectations regarding forward-looking statements or information contained in this press release include, among others, that immunology responses are a predictor of clinical benefit; that immunological findings in our first three cohorts will be consistent with findings from our fourth cohort and future clinical studies; that safety and tolerability findings in all four cohorts will be consistent with findings from future clinical studies; that results from future clinical trials will be consistent with our expectations; that we will raise enough capital, on reasonable terms and in a timely manner; that we will retain our key personnel; that we will obtain the necessary regulatory approvals related to HspE7 and Poly-ICLC in a timely manner; that sufficient HspE7 and Poly-ICLC will be available to conduct our planned clinical trials; that we will obtain timely approval from additional Investigational Review Boards; that the results from additional preclinical and clinical work, if any, will be consist
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
3. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
4. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , August 20, 2014 Phase ... in the US  KalVista Pharmaceuticals ("KalVista"), an ... (DME), today announces that it has begun a Phase ... kallikrein inhibitor, KVD001, for the treatment of DME. The ... the Beetham Eye Institute, Joslin Diabetes Center; Harvard Medical ...
(Date:8/19/2014)... , Aug. 19, 2014   Lincor ... its patient experience technology to New ... the five-year agreement, CarePoint Health will deploy Lincor,s ... Medical Center, Christ Hospital and Hoboken University Medical ... a range of software solutions to help hospitals ...
(Date:8/19/2014)... -- The Alabama Supreme Court, in a 6-3 decision on August ... mislead doctors into believing that prescription medicines the companies market ... Wyeth, and the decision came after the Supreme Court ruled ... Heninger Garrison Davis attorneys Lew Garrison and ... Danny Weeks . The decision won a clear ...
Breaking Medicine Technology:KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4Lincor Announces Agreement With CarePoint Health For State-Of-The-Art Patient Engagement Technology 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 4
... 13 Octapharma USA ... therapy development specifically for von Willebrand Disease (VWD), is now ... Food and Drug Administration (FDA) has approved wilate® ... in patients with severe VWD as well as in patients ...
... May 13 Stereotaxis, (Nasdaq: STXS ... with complex arrhythmias such as atrial fibrillation, ventricular tachycardia, ... the scientific program of the 31st Annual Heart Rhythm ... presentations and eight posters will underscore the broad clinical ...
Cached Medicine Technology:Octapharma USA Announces Availability and Distributors for wilate®, the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces Availability and Distributors for wilate®, the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces Availability and Distributors for wilate®, the First Replacement Therapy Developed Specifically for von Willebrand Disease 4New Data Demonstrate Safety, Efficacy of Stereotaxis for Patients with AFIB, VT and Congenital Defects 2New Data Demonstrate Safety, Efficacy of Stereotaxis for Patients with AFIB, VT and Congenital Defects 3New Data Demonstrate Safety, Efficacy of Stereotaxis for Patients with AFIB, VT and Congenital Defects 4New Data Demonstrate Safety, Efficacy of Stereotaxis for Patients with AFIB, VT and Congenital Defects 5New Data Demonstrate Safety, Efficacy of Stereotaxis for Patients with AFIB, VT and Congenital Defects 6
(Date:8/20/2014)... No matter how “lonely” a person may be, he ... friends to be always there for them. However, it is ... making new friends during adulthood : not only is ... of one’s family to a near-slavish devotion to career-building, the ... just is not the same as it was when one ...
(Date:8/20/2014)... 20, 2014 Building on growing ... successfully predicted stage iii and iv pressure ulcers ... situations, approached 90%. A company spokesperson commented that ... commercial or academic settings. The resulting capabilities can ... of hospital-acquired conditions to help providers avoid financial ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 “Have you recently ... auto accident and personal injury lawyer serving the greater Seattle ... incident? If so, then keep reading . , In ... individuals injured in an auto accident can use to see ... explains that a personal injury insurance claim will allow an ...
(Date:8/20/2014)... Ticketability.com has Theresa Caputo ... prices. The well-known medium has been thrilling many with ... in 19 cities, with tickets becoming available August 15. ... visit are Albany, Baltimore, Trenton, Erie, Buffalo, Philadelphia, Charlotte, ... and San Diego. The medium’s fans can obtain Theresa ...
(Date:8/20/2014)... Wisconsin (PRWEB) August 20, 2014 BuyCheapTicketsToEvents.com ... and a wide selection of tickets to many events. Cheap ... that will begin in September. , Hockey fans are enthusiastic ... to obtain tickets for games. Now is the time to ... to begin in mere months. There will be a great ...
Breaking Medicine News(10 mins):Health News:‘How to Make Friends as an Adult by Just Being Yourself: Becoming a “People Person” In Three Steps or Less’ Gives Tips for Making Friends During Adulthood - Vinamy 2Health News:Jvion Achieves Benchmark Accuracy in Pressure Ulcer Prediction 2Health News:Five Questions to Determine Who Qualifies for a Personal Injury Claim Recently Released by The Jones Firm in Recent Article 2Health News:Theresa Caputo Tour Tickets for Sale at Ticketability.com Cause a Buying Frenzy Among Customers Over Their Offering of Deeply Discounted Seats 2Health News:2014 NHL Preseason Tickets Are Among Top Selling Seats at Trusted Provider BuyCheapTicketsToEvents.com 2
... pediatric research institution , ... Washington, DC (Vocus) November ... Research Institute , dedicated new research facilities today, increasing the space ... than 100,000 square feet. , , , , ,Elected officials and ...
... MedNotes offers personalized medication profiles, drug interaction and warning ... , NEW YORK, Nov. 24 ... medication and related health issues, today announced the launch ... way consumers can monitor and manage their own medications, ...
... For over a decade Ochsner Health System,has enjoyed a ... improved patient care, cost savings and increased revenues for,Ochsner,s ... New Orleans have,seen more than their share of tragedy. ... left the greater New Orleans hospital infrastructure,badly damaged. ...
... With the bWell-informed Health Plan Forecaster, Medicare shoppers can ... , NEW YORK, Nov. ... first day of the holiday shopping rush. For seniors ... options, there,s no better time to "shop" for coverage ...
... Nov. 24 In preparation for its January 1,2009 ... Francisco,s highly regarded Institute on Aging (IOA). , ... nonprofit, membership-based, "aging-in-place",program designed to help older adults and ... apartments, and neighborhoods as long as they wish or ...
... 75th Annual Stockholders Meeting of Florida’s Natural Growers ... on Monday, the 17th of November. The theme ... Value,” was appropriate since the Cooperative reported one ... despite an extremely challenging economic environment. In fact, ...
Cached Medicine News:Health News:Children's National Dedicates New Research Facility 2Health News:Children's National Dedicates New Research Facility 3Health News:Drugs.com Unveils the Next Generation Medication Safety Tool to Help Consumers Avoid Dangerous Drug Interactions 2Health News:Drugs.com Unveils the Next Generation Medication Safety Tool to Help Consumers Avoid Dangerous Drug Interactions 3Health News:Drugs.com Unveils the Next Generation Medication Safety Tool to Help Consumers Avoid Dangerous Drug Interactions 4Health News:Drugs.com Unveils the Next Generation Medication Safety Tool to Help Consumers Avoid Dangerous Drug Interactions 5Health News:Ochsner Health System, Surgical Information Systems Partner to Rebuild New Orleans Healthcare Infrastructure 2Health News:Ochsner Health System, Surgical Information Systems Partner to Rebuild New Orleans Healthcare Infrastructure 3Health News:bWell-informed(TM) Adds Medicare Plan Tools for 2008 Open Enrollment Season 2Health News:Institute on Aging Collaborates With New Program San Francisco Village 2Health News: Florida's Natural Celebrates 75 Years with Record Performance 2Health News: Florida's Natural Celebrates 75 Years with Record Performance 3
... Cruise Control is ... STAAR as a filter ... and aspiration tubing that ... the safety and efficiency ...
... The robust, compact Sleepscan Traveler provides the ... can acquire PSG data in the home, ... laboratory. Traveler sleep studies utilize the same ... in-lab studies. Sleepscan Traveler studies take full ...
... Pioneer in Digital EEG ,The company ... system presents the latest addition to ... VISION. This innovative system incorporates the ... and information management to offer you ...
"Ganzfeld" stimulations for flash VEP, flash ERG and sensory EOG. Complies with international standards of electrophysiology....
Medicine Products: